RBC Europe’s Jazz Pharmaceuticals JAZZ Stock Holding History

RBC Europe’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$88K	Buy	566 +33	+6%	+$5.08K	﹤0.01%	273
2022 Q1	$83K	Sell	533 -13	-2%	-$1.89K	﹤0.01%	301
2021 Q4	$70K	Sell	546 -257	-32%	-$33.8K	﹤0.01%	322
2021 Q3	$105K	Buy	803 +28	+4%	+$4.23K	﹤0.01%	402
2021 Q2	$138K	Buy	+775	New	+$134K	0.01%	370

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

RBC Europe's JAZZ Position: Q2 2022 in Review

RBC Europe increased its Jazz Pharmaceuticals (JAZZ) stake by 6.2% in Q2 2022, buying an estimated $5.08K and bringing the position to 566 shares worth $88K. The position accounts for ﹤0.01% of the portfolio, ranked #273.

RBC Europe first reported a position in JAZZ in Q2 2021 and has held it in 5 quarters since. The position peaked at $138K in Q2 2021. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

RBC Europe held 566 shares of Jazz Pharmaceuticals worth $88K as of Q2 2022.
RBC Europe bought 33 Jazz Pharmaceuticals shares in Q2 2022, an estimated $5.08K.
Jazz Pharmaceuticals made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #273 holding.
RBC Europe first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
RBC Europe's Jazz Pharmaceuticals position peaked at $138K in Q2 2021.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.